Inositol and Metformin Administration in Mediterranean Diet and Low-Carbohydrate Diets in Women With PCOS

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age20-40
SponsorDicle University

About this trial

Polycystic ovary syndrome (PCOS) is a common endocrine disorder frequently associated with obesity, insulin resistance (IR), and metabolic dysfunction. Although lifestyle modification is recommended as first-line therapy, the optimal dietary approach for women with PCOS remains uncertain. This randomized, controlled, open-label, parallel-group trial aims to compare the effects of a Mediterranean diet (MD) and a low-carbohydrate diet (LCD), each combined with metformin, inositol, or folic acid (active control), in obese women with PCOS and IR. A total of 102 participants will be randomly assigned to one of six intervention groups and followed for two months. Anthropometric measurements, body composition, biochemical parameters, and hedonic hunger will be assessed at baseline and after the intervention. The primary outcome is the change in insulin resistance, assessed by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), from baseline to 2 months. Secondary outcomes include changes in body composition, metabolic and biochemical parameters, and hedonic hunger.

Eligibility criteria

Qualifiers

Women aged 20-40

Diagnosed with PCOS (Rotterdam, 2004)

Insulin resistant (newly diagnosed or diagnosed within the last 3 months)

Obese according to the World Health Organization (2006) in grades 1 and 2 (BMI: 30-40 kg/m²)

Disqualifiers

Pregnant or breastfeeding women

Those undergoing/contemplating IVF treatment

Early menopause diagnosis

Diabetes diagnosis, use of oral antidiabetic agents

Trial design

Treatments tested in this trial

  • Metformin
  • İnositol
  • Folic Acid
  • Mediterranean diet
  • Low-Carbohydrate Diet

Treatment groups

90 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Sponsors and collaborators